The PDK2 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the PDK2 gene in the Raji B lymphocyte cell line. This product provides a genetically modified polyclonal pool that lacks functional PDK2 expression, enabling researchers to study the consequences of pyruvate dehydrogenase kinase 2 loss in a lymphoma-derived background. The polyclonal nature of the knockout ensures a diverse representation of gene-edited cells, suitable for downstream applications requiring population-level metabolic phenotype analysis.
The parental Raji cell line is a well-characterized human B lymphocyte model originating from a Burkitt lymphoma. Raji cells exhibit antigen-presenting capabilities and are widely utilized in immunology and cancer biology research. Their derivation from a highly proliferative lymphoblastoid tumor makes them particularly relevant for investigating metabolic adaptations in cancer, including the Warburg effect and hypoxia-driven reprogramming. The Raji background provides a physiologically appropriate context for studying PDK2 functions in B-cell malignancies.
PDK2 functions as a key regulatory kinase that phosphorylates and inactivates the pyruvate dehydrogenase complex (PDHA1 and PDHB subunits), effectively restricting pyruvate entry into the tricarboxylic acid (TCA) cycle. This phosphorylation event is mediated through direct interaction with the pyruvate dehydrogenase E2 component (DLAT) and the E3 binding protein (PDHX). Transcriptionally, PDK2 is upregulated by hypoxia-inducible factor 1-alpha (HIF1A) under low oxygen conditions, and its activity is further modulated by insulin, AMPK, and PI3K/AKT signaling. Consequently, PDK2 inactivation reduces acetyl-CoA production and TCA cycle flux, promoting glycolytic lactate generation and ATP synthesis through cytoplasmic pathways. The protein thereby occupies a central node connecting HIF1A signaling, AMPK sensing, and insulin-regulated glucose metabolism.
In the context of Raji lymphoma cells, endogenous PDK2 activity likely contributes to the metabolic shift toward aerobic glycolysis characteristic of Burkitt lymphoma, facilitating cell proliferation and survival under fluctuating microenvironmental oxygen tensions. Disruption of PDK2 in these polyclonal cells provides a powerful system to interrogate how forced reversal of the glycolytic phenotype impacts mitochondrial respiration, reactive oxygen species handling, and biosynthetic pathway dependence. This model is especially valuable for dissecting the role of PDK2 in antigen-presenting cell metabolism and lymphoma pathophysiology, offering a relevant platform for evaluating therapeutic vulnerabilities linked to pyruvate dehydrogenase regulation.
Researchers can employ this PDK2 knockout polyclonal Raji model in cancer metabolism studies, Warburg effect investigation, and hypoxia signaling research. Typical experimental workflows include Western blotting for PDK2 and phospho-PDH levels, Seahorse metabolic flux analysis to measure oxygen consumption and extracellular acidification rates, lactate production and glucose uptake assays, and RT-qPCR profiling of metabolic genes such as HIF1A, PKM2, and GLUT1. Additional applications extend to drug target validation for metabolic disorders, co-immunoprecipitation studies of PDK2-PDH complex integrity, and apoptosis assays under hypoxic challenge. For further details, please contact Ascent Research.
